Information Provided By:
Fly News Breaks for April 20, 2015
BCRX
Apr 20, 2015 | 08:01 EDT
BofA/Merrill upgraded BioCryst to Neutral and increased its price target to $12 from $8. The firm has increased conviction in lead candidate BCX4161 following competitor data from Dyax in HAE patients.
News For BCRX From the Last 2 Days
There are no results for your query BCRX